Possible effects of repeated exposure to ibuprofen and acetaminophen on the intestinal immune response in young infants

Medical Hypotheses

Volumn 87, Issue , 2016, Pages 90-96

  Langhendries, J P ^a   Allegaert, K ^b   Van Den Anker, J N ^c,d,e   Veyckemans, F ^f   Smets, F ^f  

^a CHC Site St Vincent ^*  (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FOOD ANTIGEN; IBUPROFEN; PARACETAMOL; PROSTAGLANDIN E2; NONSTEROID ANTIINFLAMMATORY AGENT;

ALLERGIC REACTION; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; DENDRITIC CELL; ENZYME INHIBITION; HUMAN; IMMUNE DYSREGULATION; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFANCY; INNATE IMMUNITY; INTESTINE MUCOSA; LAMINA PROPRIA; MICROFLORA; MUCOSAL IMMUNITY; NONHUMAN; ONTOGENY; PERINATAL DRUG EXPOSURE; PROSTAGLANDIN SYNTHESIS INHIBITION; ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; BIOSYNTHESIS; CHILD; DRUG EFFECTS; IMMUNOLOGY; INFANT; METABOLISM; NEWBORN; PRESCHOOL CHILD;

ACETAMINOPHEN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DINOPROSTONE; HUMANS; IBUPROFEN; IMMUNE TOLERANCE; INFANT; INFANT, NEWBORN; INTESTINAL MUCOSA; MODELS, ANIMAL; MODELS, IMMUNOLOGICAL;

EID: 84955695511     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.11.012     Document Type: Article

References (72)

1. La Rocca C., Carbone F., Longobardi S., Matarese G. The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus. Immunol Lett 2014, 162:41-48.
2. Samstein R.M., Josefowicz S.Z., Arvey A., Treuting P.M., Rudensky A.Y. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell 2012, 150:29-38.
3. Mold J.E., Michaelsson J., Burt T.D., Muench M.O., Beckerman K.P., Busch M.P., et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 2008, 322:1562-1565.
4. Mold J.E., Mc Cune J.M. Immunological tolerance during fetal development: from mouse to man. Adv Immunol 2012, 115:73-111.
5. Williams Z. Inducing tolerance to pregnancy. N Engl J Med 2012, 367:1159-1161.
6. Burlingham W.J. A lesson in tolerance - maternal instruction to fetal cells. N Engl J Med 2009, 360:1355-1357.
7. + regulatory T-cell subset. Immunology 2004, 112:38-43.
8. Gaunt G., Ramin K. Immunological tolerance of the human fetus. Am J Perinatal 2001, 18:299-312.
9. Sudo N., Sawamura S., Tanaka K., Aiba Y., Kubo C., Koga Y. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol 1997, 159:1739-1745.
10. Sommer F., Bäckhed F. The gut microbiota - masters of host development and physiology. Nat Rev Microbiol 2013, 11:227-238.
11. Putignani L., Del Chierico F., Petrucca A., Vernocchi P., Dallapiccola B. The human gut microbiota: a dynamic interplay with the host from birth to senescence settled during childhood. Pediatr Res 2014, 76:9-10.
12. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
13. Brandtzaeg P. History of oral tolerance and mucosal immunity. Ann N Y Acad Sci 1996, 778:1-27.
14. Strobel S., Mcl Mowat A. Immune responses to dietary antigens: oral tolerance. Immunol Today 1998, 19:173-181.
15. Strickland D.H., Judd S., Thomas J.A., Larcombe A.N., Sly P.D., Holt P.G. Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control. Mucosal Immunol 2011, 4:43-52.
16. Newberry R.D., Stenson W.F., Lorenz R.G. Cyclooxygenase-2 dependent arachidonic acid metabolites are essential modulators of the intestinal immune responses to dietary antigen. Nat Med 1999, 5:900-906.
17. + adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006, 177:246-254.
18. Broere F., du Pré M.F., van Berkel L.A., Garssen J., Schmidt-Weber C.B., Lambrecht B.N., et al. Cyclooxygenase-2 in mucosal DC mediates induction of regulatory T cells in the intestine through suppression of Il-4. Mucosal Immunol 2009, 2:254-264.
19. Sevelsted A., Stokholm J., Bonnelykke K., Bisgaard H. Cesarean section and chronic immune disorders. Pediatrics 2015, 135:e92-98.
20. Wang J.-Y., Liu F.L., Chen C.Y., Huang Y.W., Hsiung C.A., Tsai H.J. Acetaminophen and/or antibiotic use in early life and the development of childhood allergic diseases. Int J Epidemiol 2013, 42:1087-1099.
21. Zeissig S., Blumberg R.S. Life at the beginning: perturbation of the microbiota by antibiotics in early life and its role in health and disease. Nat Immunol 2014, 15:307-310.
22. Horton D.B., Scott F.I., Haynes K., Putt M.E., Rose C.D., Lewis J.D., et al. Antibiotic exposure and juvenile arthritis: a case-control study. Pediatrics 2015, 136:e333-343.
23. Kronman M.P., Zaoutis T.E., Haynes K., Feng R., Coffin S. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012, 130:e794-803.
24. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002, 347:911-920.
25. Goldszmid R.S., Trinchieri G. The price of immunity. Nat Immunol 2012, 13:932-938.
26. Warner J.O. The early life origins of asthma and related allergic disorders. Arch Dis Child 2004, 89:97-102.
27. Bauer A.Z., Kriebel D. Prenatal and perinatal analgesic exposure and autism: an ecological link. Environ Health 2013, 12:41-53.
28. Beasley R., Clayton T., Crane J., von, Mutius E., Lai C.K., Montefort S., Stewart A. Association between acetaminophen use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6-7 years: analysis from Phase Three of the ISAAC programme. Lancet 2008, 372:1039-1048. ISAAC Phase Three Study Group.
29. Muc M., Padez C., Pinto A.M. Exposure to acetaminophen and antibiotics in early life and elevated risk of asthma in childhood. Adv Exp Med Biol 2013, 788:393-400.
30. Shaheen S.O., Newson R.B., Smith G.D., Henderson A.J. Prenatal acetaminophen exposure and asthma: further evidence against confounding. Int J Epidemiol 2010, 39:790-794.
31. Allegaert K., Veyckemans F., Tibboel D. Clinical practice: analgesia in neonates. Eur J Pediatr 2009, 168:765-770.
32. Toussaint K., Yang X.C., Zielinski M.A., Reigle K.L., Sacavage S.D., Nagar S., et al. What do we (not) know about how acetaminophen (acetaminophen) works?. J Clin Pharm Ther 2010, 35:617-638.
33. Graham G.G., Davies M.J., Day R.O., Mohamudally A., Scott K.F. The modern pharmacology of acetaminophen: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacol 2013, 21:201-232.
34. Hinz B., Cheremina O., Brune K. Acetaminophen (acetaminophen) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2007, 22:382-390.
35. Hinz B., Brune K. Acetaminophen and cyclooxygenase inhibition: is there a cause of concern?. Ann Rheum Dis 2012, 71:20-25.
36. Dang D., Wang D., Zhang C., Zhou W., Zhou Q., Wu H. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS ONE 2013, 8:e77888.
37. Terrin G., Conte F., Scipione A., Bacchio E., Conti M.G., Ferro R., et al. Efficacy of acetaminophen for the treatment of patent ductus arteriosus in preterm neonates. Ital J Pediatr 2014, 40:21.
38. Terrin G., Conte F., Oncel M.Y., Scipione A., McNamara P.J., Simons S. Acetaminophen for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2015.
39. Rainsford K.D. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacol 2009, 17:275-342.
40. van Overmeire B., Smets K., Lecoutere D., Van de Broeck H., Weyler J., De Groote K. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000, 343:674-681.
41. Purssell E. Systematic review of studies comparing combined treatment with acetaminophen and ibuprofen, with either drug alone. Arch Dis Child 2011, 96:1175-1179.
42. Wong T., Stang A.S., Ganshorn H., Hartling L., Maconochie I.K., Thomsen A.M. Combined and alternating acetaminophen and ibuprofen therapy for febrile children. Cochrane Database Syst Rev 2013, 10:CD009572.
43. + T cells. J Immunol 2005, 175:1483-1490.
44. Kunikata T., Yamane H., Segi E., Matsuoka T., Sugimoto Y., Tanaka S., et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol 2005, 6:524-531.
45. Whitehouse M.W. Prostanoids as friends, not foes: further evidence from the interference by cyclooxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats. Inflammacopharmacology 2005, 12:481-492.
46. Gibbons D.L., Spencer J. Mouse and human intestinal immunity: same ballpark, different players; different rules, same score. Mucosal Immunol 2011, 4:148-157.
47. Cheelo M., Lodge C.J., Dharmage S.C., Simpson J.A., Matheson M., Heinrich J., et al. Acetaminophen exposure in pregnancy and early childhood and development of childhood asthma: a systematic review and meta-analysis. Arch Dis Child 2015, 100:81-89.
48. Lowe A.J., Carlin J.B., Bennett C.M., Hosking C.S., Allen K.J., Robertson C.F., et al. Acetaminophen use in early life and asthma: prospective birth cohort study. Br Med J 2010, 341:c4616.
49. Smyth E.M., Grosser T., Wang M., et al. Prostanoids in health and disease. J Lipid Res 2009, 50:S423-S428.
50. Harizi H., Gualde N. The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. Tissue Antigens 2005, 65:507-514.
51. Boniface K., Bak-Jensen K.S., Li Y., et al. Prostaglandine E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signalling. J Exp Med 2009, 206:535-548.
52. Langhendries J.P., Van Overmeire B. Prostaglandines, Anti-inflammatoires non Stéroïdiens (AINS) et Rein Périnatal: Un Subtil Compromis. Médicaments. Néphrotoxicité. Insuffisance rénale aigue chez le nouveau-né 2001, 36-59. Elsevier, Paris.
53. Hooper L.V., Wong M.H., Thelin A., et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001, 291:881-884.
54. Persson E.K., Scott L.S., Mowat A.M.cI., et al. Dendritic cell subsets in the intestinal lamina propria: ontogeny and function. Eur J Immunol 2013, 43:3098-3107.
55. + dendritic cells: master regulators of tolerance?. Trends Immunol 2011, 32:412-419.
56. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7:379-390.
57. Vuillermin P.J., Ponsonby A.L., Saffery R., et al. Microbial exposure, interferon gamma gene demethylation in naive T-cells, and the risk of allergic disease. Allergy 2009, 64:348-353.
58. Awasthi A., Murugaiyan G., Kuchroo V. Interplay between effector Th17 and regulator T Cells. J Clin Immunol 2008, 28:660-670.
59. Eisenstein E.M., Williams C.B. The Treg/Th17 cell balance: a new paradigm for autoimmunity. Pediatr Res 2009, 65:26R-31R.
60. Guarner F., Bourdet-Sicard R., Brandtzaeg P., et al. Mechanisms of disease: the hygiene hypothesis revisited. Nat Clin Pract Gastroenterol Hepatol 2006, 3:275-284.
61. Huehn J., Polansky J.K., Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage. Nat Rev Immunol 2009, 9:83-89.
62. Morley R., Saffery R., Douglas F., et al. Epigenetics and neonatology: the birth of a new area. NeoReviews 2009, 10:e387-e395.
63. Szyf M. The early life environment and the epigenome. Biochim Biophys Acta 2009, 1790:878-885.
64. Ohlsson A., Shah P.S. Acetaminophen (acetaminophen) for patent ductus arteriosus in preterm or low-birth-weight infants. Cochrane Database Syst Rev 2015, 11(3):CD010061.
65. Prymula R., Siegrist C.-A., Chlibek R., et al. Effect of prophylactic acetaminophen administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009, 374:1339-1350.
66. Chen W. IDO: more than an enzyme. Nat Immunol 2011, 12:809-811.
67. Hammer G.E., Turer E.E., Taylor K.E., Fang C.J., Advincula R., Oshima S. Dendritic cell expression of A20 preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol 2012, 12:1184-1193.
68. Strober W., Murray P.J., Kitani A., Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006, 6:9-20.
69. Barnes M.J., Griseri T., Johnson A.M.F., Young W., Powrie F., Izcue A. CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal Immunol 2013, 6:324-334.
70. Benson J.M., Shepherd D.M. Dietary ligands of the aryl hydrocarbon receptor induce anti-inflammatory and immunoregulatory effects on murine dendritic cells. Toxicol Sci 2011, 12:327-338.
71. Lee J.S., Cella M., Mc Donald K.G., Garlanda C., Kennedy G.D., Nukaya M., et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol 2012, 13:144-152.
72. Apetoh L., Quintana F.J., Pot C., Joller N., Xiao S., Kumar D., et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory cells induced by Il-27. Nat Immunol 2010, 11:854-862.